3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
FED
1
Study Type
Observational
1
Sponsor
Cancer Type
Sarcoma
1
Plasma cell
1
Conditions
Multiple Myeloma
47
Recurrence
10
Neoplasms, Plasma Cell
5
Sarcoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Smoldering Multiple Myeloma
1
Sarcoma, Clear Cell
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Neoplasms
1
Neoplasm, Residual
1
Myoepithelioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Histiocytoma, Angiomatoid Fibrous
1
Interventions
Cyclophosphamide
37
fludarabine phosphate
34
Mycophenolic Acid
27
Peripheral Blood Stem Cell Transplantation
26
Cyclosporine
25
Whole-Body Irradiation
22
Antilymphocyte Serum
19
Busulfan
18
Radiotherapy
17
Filgrastim
17
Tacrolimus
16
Methotrexate
13
Methylprednisolone
11
Cord Blood Stem Cell Transplantation
11
Melphalan
10
Etoposide
8
Thiotepa
4
Therapeutics
4
Sirolimus
4
fludarabine
3
Polymerase Chain Reaction
3
Granulocyte Colony-Stimulating Factor
3
Cytarabine
3
Carmustine
3
Amplified Fragment Length Polymorphism Analysis
3
Alemtuzumab
3
sargramostim
2
aldesleukin
2
Voriconazole
2
Prednisone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dendritic Cell Sarcoma, Interdigitating
×
selinexor
×
Plasma cell
×
Clear all
NCT06452446
2025-02-10
Selinexor
Durham VA Medical Center
Active not recruiting
20 enrolled